An attempt to stretch the benefit: Re-challenge with PARP inhibitors in ovarian cancer.

Poly (ADP-ribose) polymerase (PARP) inhibitors exploit synthetic lethality in homologous recombination deficient (HDR) cells and are standard of care treatment in newly diagnosed and relapsed epithelial ovarian cancer (EOC). A recent article demonstrated that a second course of olaparib can be safely administered to women with BRCA mutated EOC.